OnKure Therapeutics (OKUR) Non-Current Deffered Revenue (2020 - 2024)
OnKure Therapeutics' (OKUR) quarterly Non-Current Deffered Revenue came in at $8000.0 in Q2 2024, down 99.09% YoY from $876000.0 in Q3 2023, and up 14.29% on a QoQ basis from $7000.0 in Q1 2024.
OnKure Therapeutics (OKUR) Non-Current Deffered Revenue (2020 - 2024) Analysis & Trends
OnKure Therapeutics (OKUR) has 5 years of Non-Current Deffered Revenue data on file, last reported at $8000.0 in Q2 2024.
- Quarterly Non-Current Deffered Revenue fell 99.09% year-over-year to $8000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $8000.0 (down 99.09% YoY) and the FY2023 annual result came in at $7000.0, down 75.86% from the prior year.
- Non-Current Deffered Revenue grew to $8000.0 in Q2 2024, from $7000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $1.1 million in Q3 2023 to a low of $7000.0 in Q4 2023.
- A 5-year average of $243800.0 and a median of $57000.0 in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue soared 1519.7% — and 2024, when it tumbled 99.09%.
- Tracing OKUR's Non-Current Deffered Revenue over 5 years: stood at $36000.0 in 2020, then jumped by 1133.33% to $444000.0 in 2021, then slumped by 93.47% to $29000.0 in 2022, then plunged by 75.86% to $7000.0 in 2023, then increased by 14.29% to $8000.0 in 2024.
- The last three Non-Current Deffered Revenue figures came in at $8000.0 (Q2 2024), $7000.0 (Q1 2024), and $7000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 8,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 876,000.00 |
| Mar 31, 2023 | 324,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Sep 30, 2022 | 66,000.00 |
| Jun 30, 2022 | 55,000.00 |
| Mar 31, 2022 | 57,000.00 |
| Dec 31, 2021 | 444,000.00 |
| Sep 30, 2021 | 284,000.00 |
| Jun 30, 2021 | 363,000.00 |
| Mar 31, 2021 | 32,000.00 |
| Dec 31, 2020 | 36,000.00 |